Words for clinical notes
Search 5,131 terms by clinical wording, everyday description, or note example.
| Word | Plain-English search cue | Original note example | SOAP section | Writing task |
|---|---|---|---|---|
amitriptyline | tricyclic antidepressant with an active nortriptyline metabolite | The amitriptyline result is reported separately from nortriptyline. | Objective | Drug levels - named analytes and exposure reports |
analytical interference | substance or sample property alters the reported measurement | Possible analytical interference was discussed with the laboratory before interpreting the value. | Assessment | Drug concentrations, exposure and assay interpretation |
anticholinergic burden | combined effects of medicines with anticholinergic activity | The review identifies high anticholinergic burden across the home medicines. | Assessment | Medication exposure, response and adverse-effect reasoning |
apparent oral clearance | apparent clearance after oral dosing, expressed relative to bioavailability | The model reports apparent oral clearance because absolute bioavailability was not measured. | Assessment | Drug concentrations, exposure and assay interpretation |
assay-specific target | target defined using a particular measurement method | The assay-specific target was checked before comparing results reported by two laboratories. | Assessment | Medication response, exposure and reconciliation |
assay cross-reactivity | measurement response to substances other than the intended analyte | The laboratory was asked whether assay cross-reactivity might affect the immunoassay result. | Assessment | Drug concentrations, exposure and assay interpretation |
assay imprecision | random variation on repeated measurement of the same material | The difference between near-identical repeat results may reflect assay imprecision. | Assessment | Drug concentrations, exposure and assay interpretation |
assay variability | variation attributable to measurement methods or performance | The small difference is being reviewed in light of assay variability. | Assessment | Medication exposure, response and adverse-effect reasoning |
| area under the concentration-time curve across 24 hours | The calculated AUC24 is recorded in mg*h/L. | Assessment | Drug levels - exposure and pharmacokinetics | |
augmented renal clearance | renal elimination exceeds that expected in the clinical setting | The augmented renal clearance was considered after review of the measured creatinine clearance. | Assessment | Medication response, exposure and reconciliation |
average steady-state concentration | average concentration over a dosing interval at steady state | The reported average steady-state concentration was derived from interval exposure and duration. | Assessment | Drug concentrations, exposure and assay interpretation |
| marks when a symptom started | Reports that tingling began during the bus ride. | Subjective | Sequence, exposures and use of medicines | |
below-quantitation result | analyte is below the assay's stated range for reliable quantification | The below-quantitation result was preserved with the laboratory's qualifier and units. | Assessment | Medication response, exposure and reconciliation |
below target | falls below the applicable stated goal | The measured level is below target for the specified sampling window. | Assessment | Drug levels - exposure and pharmacokinetics |
beta-D-glucan | fungal cell-wall component measured by a nonspecies-specific assay | Beta-D-glucan was reported with the laboratory cutoff and exposure history. | Objective | Molecular testing, serology and culture findings |
bioequivalence | similarity of rate and extent of absorption under specified conditions | The dispensing review documents the reference used to verify bioequivalence. | Assessment | Medication exposure, response and adverse-effect reasoning |
biological variability | physiologic variation between measurements | Day-to-day biological variability may contribute to the observed difference. | Assessment | Medication exposure, response and adverse-effect reasoning |
blinded treatment assignment | the treatment group allocated to a trial participant is concealed from specified people | The coordinator verified the study kit number. Blinded treatment assignment prevented identification of active drug versus placebo during reconciliation. | Assessment | Medication response, exposure and reconciliation |
blood-to-plasma ratio | whole-blood concentration divided by plasma concentration | The reported blood-to-plasma ratio was specific to the assay and sampling conditions. | Assessment | Drug concentrations, exposure and assay interpretation |
borrowed | used another person's medicine or device | Reports using a borrowed inhaler during the episode. | Subjective | Sequence, exposures and use of medicines |
breakthrough infection | infection develops despite an intervention intended to prevent it | Breakthrough infection was reviewed with prophylaxis exposure and adherence. | Assessment | Infection course, epidemiology and source attribution |
busulfan | alkylating agent with protocol-specific pharmacokinetic sampling | Each busulfan sample is linked to the actual infusion record. | Objective | Drug levels - named analytes and exposure reports |
calibration shift | systematic change in results related to measurement calibration | The laboratory reviewed for a calibration shift after the analyzer change. | Assessment | Drug concentrations, exposure and assay interpretation |
capacity-limited elimination | elimination is constrained by a process with finite capacity | Capacity-limited elimination was discussed in the pharmacokinetic interpretation. | Assessment | Medication response, exposure and reconciliation |
carbamazepine | antiseizure medicine with a separately measurable active epoxide metabolite | The carbamazepine and epoxide measurements appear on separate lines. | Objective | Drug levels - named analytes and exposure reports |